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Abstract
Background: The new nine-valent vaccine against human papillomavirus (HPV) includes the four HPV genotypes (6,
11, 16, and 18) that are targeted by the older quadrivalent HPV vaccine, plus five additional oncogenic types (31, 33,
45, 52, and 58) remain significantly associated with high grade lesions. We aimed to determine the prevalence of
high-risk HPV genotypes in unvaccinated subjects and the association of these genotypes with the incidence of
high-grade lesions. We also assessed which, if either, of these two HPV vaccines could have prevented these cases.
Methods: This cross-sectional study, conducted from 4 January 2010 to 30 December 2011, was composed of 595
women attending the Hospital General Universitario de Elche (Spain) gynaecology department who were positively
screened for opportunistic cervical cancer by pap smears and HPV detection during a routine gynaecological health
check. The pap smear results were classified using the Bethesda system. HPV genotyping was performed with the
Linear Array HPV genotyping test, and viruses were classified by the International Agency for Research on Cancer
assessment of HPV carcinogenicity. Odds ratios (ORs) with their 95% confidence intervals (95% CI) were estimated
by logistic regression, adjusting for age and immigrant status. The prevented fraction among those exposed
(PFe-adjusted) was determined as a measure of impact.
Results: At least one of the additional five high-risk HPV genotypes present in the nine-valent HPV vaccine was
detected in 20.5% of subjects. After excluding women with genotype 16 and/or 18 co-infection, high-risk
genotypes (31, 33, 45, 52, and 58) were associated with a higher risk of intraepithelial lesion or malignancy: adjusted
OR = 3.51 (95% CI, 1.29–9.56), PFe-adjusted = 0.72 (95% CI, 0.22–0.90). Genotypes that are still non-vaccine-targeted
were detected in 17.98% of the women, but these were not significantly associated with high-grade lesions.
Conclusion: The greater protection of the nine-valent HPV vaccine is likely to have a positive impact because, in
the absence of genotype 16 or 18 infection, these five genotypes on their own remained significantly associated
with high-grade lesions.
* Correspondence: maria.paz@unican.es
1Faculty of Nursing, University of Cantabria, Avda Valdecilla s/n. C.P.: 39008,
Cantabria, Spain
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Paz-Zulueta et al. BMC Cancer  (2018) 18:112 
DOI 10.1186/s12885-018-4033-2
Background
Human papillomavirus (HPV) infection is the most
common sexually transmitted infection in the United
States and Europe [1]. Persistent HPV infection with a
high-risk oncogenic genotype, as well as co-infection
with high-risk genotypes, contributes to neoplastic pro-
gression [2–4]. Cervical cancer (CC) and other HPV-
related cancers represent a major global public health
problem. Cervical cancer is the third most common can-
cer among women worldwide [5]. It has been found that
according to the severity of cervical lesions, the overall
prevalence of HPV increases from 12% in women with
normal cytology to 89% in women with CC [6]. The
most frequent viral types are HPV 16, 18, 31, 33, 35, 45,
52 and 58. However, there are differences of specific type
prevalences according to the region analysed. HPV 16
and 18 are the two most prevalent types worldwide [7].
HPV genotypes 16 and 18 cause 70% of cervical cancer
cases as well as an even higher proportion of other
cancers associated with HPV infection, such as cancer of
the vulva, vagina, penis, anus, and oropharynx [8–10].
Two preventive strategies are used in combination to
prevent cervical cancer: vaccination against HPV (pri-
mary prevention) and cervical screening programmes
(secondary prevention). Cervical smears allow the detec-
tion of pre-cancerous lesions and cancer. Although it is
a very effective method, its implementation only helps to
prevent cervical cancer [11, 12]; there are no screening
tests for other types of HPV-related cancer. In Spain,
cervical screening is available but not mandatory.
Cervical screening is performed opportunistically, its
success depends on participant uptake.
In Europa, there are currently three vaccines
authorised against HPV. The bivalent HPV vaccine
Cervarix® provides protection against HPV 16 and 18
(high-risk oncogenic genotypes); the quadrivalent HPV
vaccine Gardasil® provides protection against HPV 6 and
11 (low-risk oncogenic genotypes related with the
appearance of 90% of genital warts) [13] together with
genotypes 16 and 18. Nowadays in Spain, we use
bivalent HPV vaccine Cervarix® and quadrivalent HPV
vaccine Gardasil®. Depending on the region, one or other
vaccine is included in the childhood immunization
schedule. The last approved nine-valent HPV vaccine
Gardasil9® provides protection against HPV 6, 11, 16, 18,
31, 33, 45, 52, and 58 [14]. This new vaccine extends
protection to a further five oncogenic types (HPV 31, 33,
45, 52, and 58), in addition to the four types included in
the original Gardasil®. Thus, the nine-valent HPV vaccine
is estimated to potentially prevent close to 90% of cancers
of the cervix, vulva, vagina, and anus, as well as 80% of
pre-cancerous lesions [15]. Scientific evidence regarding
the safety profile [16], immunogenicity [17, 18], and safety
and efficacy [19–22] of these vaccines is well established.
The aims of our study were to determine the prevalence of
high-risk HPV genotypes and analyse how effective the pro-
tection offered by the quadrivalent HPV vaccine and the new
nine-valent HPV vaccine would be in this population as well
as to investigate the association with and potential impact of
these genotypes on the incidence of high-grade lesions.
Methods
Type of study
This was a cross-sectional study of 595 women.
Population
During the study period (January 4,2010 to December
30,2011), women who came to the gynecology depart-
ment of the Hospital General Universitario de Elche
(Spain) for a routine gynecological check-up were
treated according to the cervical cancer screening proto-
col: a combined Pap smear test and HPV screening. For
our study, we included 595 consecutive women in whom
the linear combined HPV genotyping test had detected
HPV infection in a cervical smear.
Data sources
We obtained the data for each patient from computer-
ized hospital records of gynaecology and microbiology
services. When necessary, this information was com-
pleted with data from paper medical records and the
histopathology department Cliniviewer.
Variables
The primary variables included date of birth, country of
birth, patient’s VPH vaccine status, Pap smear result,
and determination of HPV genotype by polymerase
chain reaction (PCR) assay.
The results of the pap smears were classified according
to the Bethesda 2001 histological classification [23].
Positive pap smears were defined as those that presented
abnormal epithelial cells. The result was classified as:
atypical squamous cells of undetermined significance or
atypical glandular cells (ASC-US/AGC), low grade squa-
mous intraepithelial lesion (LSIL), high grade squamous
intraepithelial lesion (HSIL), squamous cell carcinoma,
adenocarcinoma in situ, or adenocarcinoma.
HPV genotyping was performed using the Linear
Array HPV genotyping test (Roche Diagnostics), a quali-
tative in vitro assay that utilizes the amplification of
target DNA by PCR and nucleic acid hybridization and
detects 37 HPV genotypes: 6, 11, 16, 18, 26, 31, 33, 35,
39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64,
66, 67, 68, 69, 70, 71, 72, 73 (MM9), 81, 82 (MM4), 83
(MM7), 84 (MM8), IS39, and CP6108. HPV types were
classified according to the World Health Organization
(WHO) International Agency for Research on Cancer
(IARC) Monographs Working Group assessment of the
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carcinogenicity of different HPV types [24–26]: 13 high-
risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 68)
and 5 likely high-risk (53, 66, 70, 73 MM9, and 82
MM4). The finding of two or more high-risk genotypes
in the same patient was defined as co-infection [27].
Based on the protection that would have been provided
by the quadrivalent or new nine-valent HPV vaccines, the
high-risk genotypes were classified into [28]:
a) vaccine-targeted high-risk HPV genotypes (16 and 18);
b) quadrivalent HPV-targeted genotypes (6, 11, 16,
and 18);
c) the additional five high-risk HPV genotypes present in
the nine-valent HPV vaccine (31, 33, 45, 52, and 58);
d) high-risk HPV types other than 16 and 18 (31, 33,
35, 39, 45, 51, 52, 56, 58, 59, and 68); and
e) other non-vaccine targeted high-risk types (35, 39,
51, 56, 59, and 68).
Statistical analysis
For the categorical and discrete variables, proportions
were estimated using the Pearson Chi-squared test to
make comparisons and using Fisher’s exact test when
necessary. Continuous variables were expressed as the
mean and standard deviation (SD); a Student’s t-test was
used for comparisons following normality testing using a
Shapiro-Wilk test.
Cytological results were classified as being a “Non-high-
grade lesion” (smear negative for intraepithelial lesion,
ASC-US/AGC, or LSIL) or a “High-grade lesion” (HSIL,
squamous cell carcinoma, adenocarcinoma in situ, or
adenocarcinoma), and this classification was treated as a
dependent variable in the logistic regression models.
As a measure of association, the crude odds ratios
(ORc) as well as the odds ratios adjusted (ORa) for age
(continuous variable) and immigrant status were esti-
mated by unconditional logistic regression, together with
their 95% confidence intervals (95% CI).
As a measure of impact, the adjusted attributable
fraction in the total exposed (AFe-adjusted) was calculated
using the formula [(ORa – 1)/ORa] together with its 95%
CI using the formula [((lower limit 95% CI of the ORa –
1)/lower limit 95% CI of the ORa) to ((upper limit 95%CI
of the ORa − 1)/upper limit 95% CI of the ORa)] when the
ORa was statistically significant. The alpha error was set
at 0.05, and all p were two-sided. All statistical analyses
were performed using IBM SPSS Statistics V22.0.
Results
Of the total participants, 73.11% (95% CI, 69.43–76.76) of
women presented with at least one high-risk HPV genotype.
High-risk HPV genotypes not targeted by the quadrivalent
HPV vaccine were found in 38.49% of women (95% CI,
34.49–42.48%). At least one of the additional five high-risk
HPV genotypes present in the nine-valent HPV vaccine (31,
33, 45, 52, or 58) was found in 20.50% of women (95% CI,
17.18–23.83%) (Table 1).
Table 1 High-risk HPV genotypes, vaccine-targeted high-risk HPV genotypes, and single type infections and multiple type infections
Total Single HPV type Multiple HPV typesa
n = 595 % 95% CI n = 595 % 95% CI n = 595 % 95% CI
HPV genotypes
Vaccine-targeted high-risk HPV genotypes
16 180 30.08 26.32 33.85 65 10.92 8.33 13.52 115 19.33 16.07 22.59
18 32 5.38 3.48 7.28 6 1.01 0.12 1.90 26 4.37 2.64 6.10
Additional five high-risk HPV genotypes present in the nine-valent HPV vaccine
31 56 9.41 6.98 11.84 19 3.19 1.70 4.69 37 6.22 4.19 8.24
33 27 4.71 2.92 6.49 6 1.01 0.12 1.90 21 3.53 1.96 5.10
45 18 3.03 1.57 4.49 4 0.67 0.18 1.71 14 2.35 1.05 3.66
52 85 14.29 11.39 17.18 8 1.35 0.34 2.35 77 12.94 10.16 15.72
58 37 6.22 4.19 8.24 4 0.67 0.18 1.71 33 5.55 3.62 7.47
Quadrivalent HPV and nine-valent HPV non-vaccine-targeted high-risk HPV genotypes
35 17 2.86 1.43 4.28 3 0.50 0.10 1.47 14 2.35 1.05 3.66
39 46 7.73 5.50 9.96 9 1.51 0.45 2.58 37 6.22 4.19 8.24
51 69 11.60 8.94 14.25 14 2.35 1.05 3.66 55 9.24 6.83 11.66
56 55 9.24 6.83 11.66 2 0.34 0.04 1.21 53 8.91 6.54 11.28
59 28 4.71 2.92 6.49 6 1.01 0.12 1.90 22 3.70 2.10 5.30
68 13 2.19 0.93 3.44 0 0.00 0.00 0.62 13 2.19 0.93 3.44
aWomen infected with multiple human papillomavirus (HPV) types: high-risk, likely high-risk HPV or low-risk genotypes [11]
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High-risk HPV genotypes not targeted by either the
quadrivalent HPV or the nine-valent HPV vaccine (35,
39, 51, 56, 59, or 68) were found in 17.98% of women
(95% CI, 14.81–21.15%) (Table 1).
The mean age of the women included in this study
was 34.34 years [SD: 10.70]; 89.75% were Spanish. Of the
participants, 41.36% had at least one smear with mor-
phological changes (ASC-US, LSIL, HSIL, squamous cell
carcinoma, adenocarcinoma in situ, or adenocarcinoma).
The prevalence of ASC-US was 8.14% (95% CI, 5.85–
10.43), that of LSIL was 19.49% (95% CI, 16.21–22.77),
and that of HSIL was 11.53% (95% CI, 8.86–14.19). The
prevalence of cancerous lesions (squamous cell carcin-
oma, adenocarcinoma in situ, or adenocarcinoma) was
2.20% (95% CI, 0.93–3.47) (Additional file 1).
A single low-risk genotype (6, 11, 42, 43 or 44) was
detected in 33.61% of the women (95% CI, 29.73–37.49),
and a single likely high-risk genotype was detected in
25.88% (95% CI, 22.28–29.49). A single high-risk geno-
type was detected in 45.04% of participants (95% CI,
40.96–49.12), and two high-risk genotypes were detected
in the 20.50% (Additional file 1). The most common
multiple infections were by genotype 16 (19.33%), 52
(12.94%), or 51(9.24%) (Table 1). Genotype 16 was the
most commonly detected HPV genotype, found in
30.08% of study participants (95% CI, 26.32–33.85).
Genotypes 16 and/or 18 were detected in 35.46% of the
women (Table 2). When we analysed the percentages of
infection prevalence for the additional five high-risk
HPV genotypes present in the nine-valent HPV vaccine,
we found that 14.29% of women were infected by geno-
type 52, 9.41% by genotype 31, 6.22% by genotype 58,
4.71% by genotype 33, and 3.03% by genotype 45 (Table
1). Regarding the percentages of infection by high-risk
HPV genotypes that are not targeted by either the
quadrivalent or nine-valent HPV vaccine, we found that
11.60% of subjects were infected by genotype 51, 9.24%
by genotype 56, 7.73% by genotype 39, 4.71% by geno-
type 59, 2.86% by genotype 35, and 2.19% by genotype
68 (Table 2).
Table 3 shows the crude and adjusted measures of associ-
ation (OR) and impact (AFe) of the risk of high-grade
lesions, in relation to the HPV genotype and its potential
protection by the quadrivalent and nine-valent HPV
vaccines. After adjusting for age and immigrant status, the
presence of HPV genotype 16 or 18 individually increased
the possibility of having a high-grade lesion by 10.40-fold.
The concomitant presence of both of these genotypes in-
creased the risk of lesion as follows: adjusted OR= 63.58;
linear p trend < 0.001; AFe = 0.98 (95% CI, 0.88–1.00). The
presence of a high-risk genotype not covered by the quadri-
valent HPV vaccine increased the risk of a high-grade lesion
significantly, although to a lesser extent than the presence of
genotype 16 or 18: adjusted OR= 2.71 (95% CI, 1.05–7.01).
By sub-dividing these genotypes based on the ability
of the new nine-valent HPV vaccine to protect against
them, we found that although the presence of high-
risk genotypes not covered by the new nine-valent
HPV vaccine was not associated with a significant
increase in the risk of lesions (adjusted OR = 1.76;
95% CI, 0.54–1.70), the presence of a high-risk geno-
type not covered by the quadrivalent HPV vaccine
but covered by the new nine-valent HPV vaccine was
associated with a significant increase in this risk
Table 2 Characteristics of the studied population, distribution of
HPV genotypes, and histological classification of cervical smears
Total
n = 595 % 95% CI
Age (years): Mean [SD] 34.34 [10.70] 33.48 35.20
Country of origin
Spain 534 89.75 87.23 92.27
Other 61 10.25 7.73 12.77
Number low-risk oncogenic HPVa
1 genotype 200 33.61 29.73 37.49
2 genotypes 63 10.59 8.03 13.15
3 genotypes 15 2.52 1.18 3.87
4 genotypes 6 1.01 0.12 1.90
Number likely high-risk oncogenic HPVa
1 genotype 154 25.88 22.28 29.49
2 genotypes 12 2.02 0.80 3.23
3 genotypes 1 0.17 0.00 0.93
Number high-risk oncogenic HPVa
1 genotype 268 45.04 40.96 49.12
2 genotypes 122 20.50 17.18 23.83
3 genotypes 30 5.04 3.20 6.88
4 genotypes 14 2.35 1.05 3.66
5 genotypes 1 0.17 0.00 0.93
Results cervical smearb
NILMc 272 46.10 42.00 50.21
Inflammatory 70 11.86 9.17 14.56
Warts 1 0.17 0.00 0.94
ASC-US/ASC-H 48 8.14 5.85 10.43
LSIL 115 19.49 16.21 22.77
HSIL 68 11.53 8.86 14.19
Carcinoma/Adenocarcinoma 13 2.20 0.93 3.47
Result not available 3 0.51 0.11 1.48
Missing 5
aClassification of human papillomavirus (HPV) types according to the World
Health Organization International Agency for Research on Cancer (IARC)
Monographs Working Group assessment of the carcinogenicity of different
HPV types [25–27]
bHistological classification Bethesda 2001 System [24]
cNegative for intraepithelial lesion or malignancy
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(adjusted OR = 3.51, 95% CI, 1.29–9.56; adjusted AFe
= 0.72, 95% CI, 0.22–0.90) (Table 4).
Discussion
Our results show that in the absence of infection with
HPV genotypes 16 or 18, the greater level of protection
provided by the new nine-valent HPV vaccine compared
with that provided by the quadrivalent HPV vaccine is
likely to have a measurable impact. The extra five HPV
genotypes remained significantly associated with high
grade lesions.
Our results show a high prevalence of infection by
a single high-risk oncogenic HPV genotype (45.04%)
[29–32]. The percentage of women who presented a
morphological change in their pap smear (positive
screening) was also high (41.36%) [33, 34]. This could
be due to the characteristics of our sample, since our
study was not conducted on the general population
but rather it specifically included women with a
confirmed HPV infection. Similarly, with respect to
the prevalence of genotypes 16 and 18 in our sample,
we found higher prevalences (30.08% and 5.38%,
respectively) than those described in previous
population-based studies [29, 32]. Our findings are
closer to those reported by Garcia Espinosa et al.
[35], who showed that the most common HPV geno-
types found in all specimens were genotypes 16
(26.0%), 31 (10.7%), and 58 (8.0%). In their study,
genotype 18 was detected in only 5.0% of women.
Here, the prevalence of genotype 52 was higher than
that found by other authors in national studies [36, 37].
Our results also do not coincide with the prevalence
reported by the 2016 ICO-WHO report [38], which
detected genotype 52 in 5.4% of HSIL and in 2.4% of can-
cerous lesions. This difference could be due to the high
population of immigrants from East Africa that plays an
important role in our health area; a very high prevalence
of HPV 52 infection has been reported for this geographic
area [39]. In contrast, the data published by Castellsagué
et al. and Delgado et al. [30, 40] regarding the prevalence
of HPV 52 are similar to those obtained in our study.
Castellsagué et al. found that after HPV 16, genotype 52
was the most prevalent, and Delgado et al. reported the
prevalence for genotype 52 as 12%.
The most common high-risk type detected in this
study was HPV16 which is consistent with published
studies and that vaccination will likely have a significant
impact [20–22, 41]. Furthermore, HPV genotype 16 or
18 cause 70% of cases of cervical cancer and an even
higher proportion of cancers of the vulva, vagina, penis,
anus, and oropharynx [8–10]. Thus, current HPV
vaccines (Cervarix® and Gardasil®) prevent approximately
70% of cervical cancers through protection against
genotypes 16 and 18.
Partial cross-protection against non-vaccine targeted
HPV types has been reported for both licensed vaccines,
although the clinical significance of this finding remains
uncertain [42]. In the FUTURE I / II and PATRICIA
studies, conducted in young women, the bivalent vaccine
Table 3 Prevalence of high-risk human papillomavirus genotypes according to the vaccine-targeted high-risk human papillomavirus
genotypes
Total
n = 595 % 95%CI
Regarding HPV genotype
No high-riska 160 26.89 23.24 30.54
At least 1 high-risk 435 73.11 69.46 76.76
According to the vaccine-targeted high-risk HPV genotypes
No high-riska 160 26.89 23.24 30.54
Quadrivalent HPV non-vaccine-targeted high-risk
HPV genotypesb
229 38.49 34.49 42.48
Quadrivalent HPV and nine-valent HPV non-vaccine-targeted
high-risk HPV genotypesc
107 17.98 14.81 21.15
Additional five high-risk HPV genotypes present in the
nine-valent HPV vaccined
122 20.50 17.18 23.83
Vaccine-targeted high-risk HPV genotypes
(16 or 18)
201 33.78 29.90 37.67
Vaccine-targeted high-risk HPV genotypes
(16 and 18)
5 0.84 0.27 1.95
aNo high-risk. Classification human papillomavirus (HPV) types according to the World Health Organization International Agency for Research on Cancer (IARC)
Monographs Working Group assessment of the carcinogenicity of different HPV types [25–27]
bAt least 1 of the quadrivalent HPV non-vaccine-targeted high-risk HPV genotypes (31 or 33 or 35 or 39 or 45 or 51 or 52 or 56 or 58 or 59 or 68)
cAt least 1 of the quadrivalent HPV and nine-valent HPV non-vaccine-targeted high-risk HPV genotypes (35 or 39 or 51 or 56 or 59 or 68)
dAt least 1 of the additional five high-risk HPV genotypes present in the nine-valent HPV vaccine (31 or 33 or 45 or 52 or 58)
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showed significant efficacy against HPV31, 33, 45 and
52, and the tetravalent vaccine against HPV31. The
bivalent vaccine showed significant efficacy against
CIN2 + related to HPV31 and 33 (excluding co-infection
with HPV16 and / or 18) and related to HPV45 (in-
cluded co-infection with HPV16 and / or 18) [43, 44].
The possible cross-protection of the new nine-valence
vaccine is still unknown. It would be necessary to evalu-
ate whether the nine-valence vaccine also protects
against other non-HPV oncogenic HPV types not
included in this vaccine.
Concomitant infection by both genotypes 16 and 18
also suggests an interaction, with co-infection multipli-
catively increasing the risk of high-grade lesions
(adjusted OR = 63.58), with an adjusted AFe of 90% and
98% for isolated or joint infection, respectively. Thus,
protection against infection with one of these genotypes
(16 or 18) would prevent approximately 90% of high-
grade lesions, while protection against both would
prevent 98% of the high-grade lesions present in women
co-infected with genotypes 16 and 18. These findings
support the preventive impact of both the quadrivalent
and the nine-valent HPV vaccine, as both cover
genotypes 16 and 18 [19, 42, 45, 46].
The new nine-valent HPV virus-like particle includes
the four HPV types (6, 11, 16 and 18) present in the
quadrivalent HPV vaccine, plus five additional oncogenic
types (31, 33, 45, 52, and 58) and potentially increases
the overall prevention of cervical cancer from around
70% to around 90% [47]. Our study supports this
increased efficacy. The greater level of protection by the
new nine-valent HPV vaccine compared with that of the
quadrivalent HPV vaccine is likely to have an observable
impact, given our finding that these genotypes on their
own (in the absence of infection by genotypes 16 or
18) remained significantly associated with high grade








No high-riskb 154 6 1 – 1 –
At least 1 high-risk 355 75 5.42 2.31 12.72 6.01 2.53 14.29 0.83 0.60 0.93
According to the vaccine-targeted high-risk HPV genotypes
















107 14 3.36 1.25 9.02 3.51 1.29 9.56 0.72 0.22 0.90
Vaccine-targeted
high-risk HPV
genotypes (16 or 18)
145 52 9.21 3.84 22.08 10.40 4.25 25.40 0.90 0.76 0.96
Vaccine-targeted
high-risk HPV
genotypes (16 and 18)
2 3 38.50 5.39 275.06 63.58 8.62 468.70 0.98 0.88 1.00
< 0.001 < 0.001
aIntraepithelial lesion or malignancy: high-grade squamous intraepithelial lesion or worse
Odds ratio and 95% confidence intervals. ORc denotes “crude OR”; ORa denotes “adjusted OR” OR adding to the basic model: age and immigrant status
AFe-a: Attributable fraction among the exposed, adjusted for age and immigrant status
bNo high-risk. Classification of human papillomavirus (HPV) types according to the World Health Organization International Agency for Research on Cancer (IARC)
Monographs Working Group assessment of the carcinogenicity of different HPV types [25–27]
cAt least 1 of the quadrivalent HPV non-vaccine-targeted high-risk HPV genotypes (31 or 33 or 35 or 39 or 45 or 51 or 52 or 56 or 58 or 59 or 68)
dAt least 1 of the quadrivalent HPV and nine-valent HPV non-vaccine-targeted high-risk HPV genotypes (35 or 39 or 51 or 56 or 59 or 68)
eAt least 1 of the additional five high-risk HPV genotypes present in the nine-valent HPV vaccine (31 or 33 or 45 or 52 or 58)
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lesions, with an adjusted AFe of 72%. Thus, our
results suggest that had the 121 patients who pre-
sented with at least one of these HPV genotypes (but
not genotype 16 or 18) been vaccinated with the new
nine-valent HPV vaccine, approximately 72% of the
high-grade lesions present in these women would
have been prevented. In other words, if all these 121
patients had been vaccinated, and the efficacy of the
vaccination for these genotypes (31, 33, 45, 52, and
58) was 100%, approximately 87 high-grade lesions
would have been prevented. Joura et al. showed an
efficacy of 96.7% against high-grade lesions related
with infection by HPV 31, 33, 45, 52, and 58 in their
analysis of a cohort of 14,215 women aged 16 to
26 years [22]. Monsonego et al. showed that a high
proportion of high-grade cervical lesions (60.6% of
genotyping assay-positive CIN2+) were associated
with HPV types 31, 33, 45, 52, or 58 [48].
In our study, 17.98% of women were infected with
high-risk genotypes that are not covered by either the
quadrivalent or the new nine-valent HPV vaccine. In
the absence of infection with genotypes 16 or 18,
infection with the remaining high-risk genotypes not
covered by the new nine-valent HPV vaccine (geno-
types 35, 39, 51, 56, 59, and 68) was associated with
a non-statistically significant risk of high-grade
lesions, with an AFe close to 40%.
When extrapolating our results, various aspects that
could result in lower attributable fractions in the popula-
tion must be considered. The effectiveness of the HPV
vaccines is likely less than 100%, and therefore the pro-
tection level is not 100% in 100% of the women vacci-
nated. Furthermore, we cannot rule out the false sense
of security reported by several authors [49, 50], which
can lead to a higher prevalence of risky lifestyles or
sexual habits, such as a lower use of condoms. Another
limitation is the fact that the attribution of lesions to
specific HPV types is complicated by the detection of
multiple HPV infections. Therefore, the potential benefit
of a HPV vaccine is not easily assessable.
On the other hand, another caveat is that cervical
lesion was performed on exfoliated cervical cells instead
of biopsy samples with laser dissection, so we did not
have confirmation of high-grade lesions by histological
study (biopsy). However, studies evaluating the category
HSIL compared to biopsy as gold standard support a
very high probability of an accurate diagnosis [47, 51].
In our study, the enrolled women had attended the
gynaecology department of the Hospital General Univer-
sitario de Elche (eastern Spain) testing positive for HPV
infection in the cervical smear performed during a
routine gynaecological health check in an opportunistic
cervical screening program. Since the population is lim-
ited to those attending opportunistic screening further
selected on the basis of their HPV status and not primar-
ily vaccine status, it prevents to make generalizations on
potential vaccine impact in the general population.
However, our results circumscribed to the study popula-
tion, show the prevalence of high-risk HPV genotypes in
unvaccinated subjects and the association of these geno-
types with the presence of high-grade lesions, allowing
to assess the potential impact of quadrivalent and nine-
valent HPV vaccines by using epidemiological impact
measures. One advantage of using adjusted ORs is that
derived from these adjusted OR, it is possible to estimate
as a measure of impact, the adjusted attributable fraction
in the total exposed together with its 95%CI. We think
that our methodology can complement the information
provided with other methodologies such as the one
followed by the recently published study by Capra et al.
[52], and that it could be useful for future reviews or
meta-analysis. The description of high-risk HPV epi-
demiology is a key feature for the design of strategies to
prevent cervical cancer, and the results from this study
can be used with this purpose in future reviews and
meta-analysis, in order to estimate the potential impact
of vaccination by either the quadrivalent or nine-valent
vaccine relative to other studies with similar aims.
Conclusion
HPV genotypes 16 and 18, especially in co-infection, are
the two HPV genotypes that have most impact on the
presence of high-grade lesions in our unvaccinated
population attending an opportunistic screening in east-
ern Spain. Based on our associations and impact epi-
demiological results, in the absence of infection with
HPV genotypes 16 or 18, the greater level of protection
provided by the new nine-valent HPV vaccine (five geno-
types) compared with that provided by the quadrivalent
HPV vaccine is likely to have a measurable impact be-
cause these genotypes on their own remained signifi-
cantly associated with high-grade lesions. In our
population, there is a percentage of women (17.98%)
who are infected with high-risk HPV genotypes that are
not covered by any of the currently available vaccines
(quadrivalent HPV or nine-valent HPV vaccines); how-
ever, as a whole, the impact of these HPV genotypes on
the risk of high-grade lesions appears to be lower than
the risk posed by other common HPV genotypes.
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